FDA approves Fezolinetant, a first-of-its-kind non-hormonal drug for hot flashes

Women who can’t or choose not to take hormones to relieve hot flashes, a common symptom in menopause, have always been forced to consider other, far less effective treatments. But now there is a new alternative.

The US Food and Drug Administration (FDA) has approved fezolinetant (Veozah), a non-hormonal medicine for hot flashes. Developed by Astellas Pharma, this is the second non-hormonal drug licensed for hot flashes in the US and research to date suggests it will be helpful in reducing hot flashes and night sweats.

We need better nonhormonal therapies for those women who can’t or choose not to take hormone therapy, says JoAnn Pinkerton, MD, professor of obstetrics and gynecology and director of the Midlife Health Center at the University of Virginia Health at charlottesville.

More than a million American women go through menopause each year, according to a book published by StatPearls in 2022. This happens when estrogen levels drop and women stop menstruating.

#FDA #approves #Fezolinetant #firstofitskind #nonhormonal #drug #hot #flashes

Leave a Reply

Your email address will not be published. Required fields are marked *